Dr Alex Zhavoronkov

Founder and CEO, Insilico Medicine

Dr Alex Zhavoronkov, PhD, is the founder, CEO, and CBO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and automation platforms for drug discovery. Since 2014, he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and the generation of synthetic biological and patient data.

Under his leadership, Insilico has raised over $530 million in multiple private rounds from expert biotechnology, healthcare, and financial investors, opened R&D centres in 8 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company has nominated 33 preclinical candidates, 13 of which have reached the clinical stage, and 1 program with a novel target and novel molecule has completed Phase IIa trials in IPF with favourable safety, tolerability, and encouraging dose-dependent efficacy.

Since 2012, he has published over 300 peer-reviewed research papers and 3 books. He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, and Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery Meeting (12th Annual in 2025). He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

BACK